https://dev.vigeneron.com/ 2025-04-15T10:28:58+00:00 https://dev.vigeneron.com/pipeline/ 2025-04-09T08:31:06+00:00 https://dev.vigeneron.com/news-events/ 2022-10-11T11:20:14+00:00 https://dev.vigeneron.com/partnering/ 2025-04-15T10:14:59+00:00 https://dev.vigeneron.com/about/ 2025-04-09T08:14:58+00:00 https://dev.vigeneron.com/imprint/ 2025-04-15T10:06:31+00:00 https://dev.vigeneron.com/innovative-sciences/ 2025-04-09T09:28:36+00:00 https://dev.vigeneron.com/careers/ 2025-04-15T10:35:24+00:00 https://dev.vigeneron.com/team_member/prof-dr-siegfried-priglinger/ 2021-02-15T13:27:57+00:00 https://dev.vigeneron.com/jobs/scientist-retinal-gene-therapy-m-f-x/ 2023-08-31T12:51:30+00:00 https://dev.vigeneron.com/team_member/prof-dr-gang-pei/ 2020-11-30T21:15:30+00:00 https://dev.vigeneron.com/team_member/dr-elvir-becirovic/ 2020-11-30T17:45:15+00:00 https://dev.vigeneron.com/team_member/prof-dr-stylianos-michalakis/ 2020-12-01T02:11:15+00:00 https://dev.vigeneron.com/team_member/prof-dr-martin-biel/ 2021-02-15T13:27:37+00:00 https://dev.vigeneron.com/press/vigeneron-announces-fda-rare-pediatric-disease-designation-for-vg901-and-dsmb-approval-to-advance-dose-escalation-in-phase-1b-retinitis-pigmentosa-trial/ 2025-01-08T14:37:47+00:00 https://dev.vigeneron.com/press/vigeneron-announces-fda-clearance-of-ind-for-novel-mrna-trans-splicing-gene-therapy-vg801-to-treat-stargardt-disease-and-other-abca4-linked-retinal-dystrophies/ 2024-12-18T15:13:30+00:00 https://dev.vigeneron.com/press/vigeneron-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-vg901-for-the-intravitreal-treatment-of-retinitis-pigmentosa/ 2024-04-10T08:11:01+00:00 https://dev.vigeneron.com/press/nature-communications-publication-reveals-highly-efficient-aav-delivery-of-large-genes-using-vigenerons-revert-technology/ 2023-10-26T11:41:50+00:00 https://dev.vigeneron.com/jobs/junior-research-assistant-m-f-d/ 2023-08-31T13:27:52+00:00 https://dev.vigeneron.com/jobs/biology-lab-technician-technical-assistant-bta-m-f-d/ 2023-08-31T12:27:17+00:00 https://dev.vigeneron.com/press/vigeneron-announces-ema-approval-of-clinical-trial-application-for-vg901-a-gene-therapy-to-treat-retinitis-pigmentosa/ 2023-08-22T08:08:13+00:00 https://dev.vigeneron.com/press/vigeneron-welcomes-dr-markus-kalousek-as-chief-business-strategy-officer-to-drive-next-phase-of-corporate-development/ 2023-06-30T06:54:21+00:00 https://dev.vigeneron.com/press/vigeneron-to-present-preclinical-efficacy-and-safety-data-on-intravitreal-gene-therapy-of-retinitis-pigmentosa-at-asgct/ 2023-05-12T08:36:16+00:00 https://dev.vigeneron.com/press/vigeneron-presents-preclinical-data-on-intravitreal-gene-therapy-of-stargardt-disease-at-esgct/ 2022-10-11T11:03:28+00:00 https://dev.vigeneron.com/media/bioworld-vigeneron-carves-out-space-in-evolving-aav-gene-therapy-landscape/ 2022-05-23T07:45:18+00:00 https://dev.vigeneron.com/media/pharmatimes-2022-vigeneron-and-daiichi-sankyo-to-develop-therapy-for-eye-diseases/ 2022-05-10T10:54:08+00:00 https://dev.vigeneron.com/press/vigeneron-announces-follow-on-collaboration-with-daiichi-sankyo-to-develop-a-novel-gene-therapy-for-prevalent-eye-diseases/ 2022-06-22T13:17:32+00:00 https://dev.vigeneron.com/press/vigeneron-signs-gene-therapy-strategic-collaboration-and-option-agreement-with-regeneron-for-one-inherited-retinal-disease-target/ 2022-06-22T12:58:51+00:00 https://dev.vigeneron.com/media/endpoints-2022-building-on-its-retinal-disease-expertise-regeneron-signs-eye-focused-gene-therapy-pact-with-german-biotech/ 2022-05-09T14:47:44+00:00 https://dev.vigeneron.com/media/biopharma-dive-2022regeneron-in-search-of-an-eye-gene-therapy-turns-to-a-young-biotech/ 2022-05-10T10:54:26+00:00 https://dev.vigeneron.com/media/fierce-biotech-2022-hunting-for-next-big-eye-disease-drug-regeneron-gets-deeper-into-gene-therapies-with-vigeneron-pact/ 2022-05-10T09:23:48+00:00 https://dev.vigeneron.com/press/vigeneron-announces-research-collaboration-with-daiichi-sankyo-to-evaluate-vgaav-for-novel-ophthalmic-gene-therapy/ 2021-01-18T16:34:40+00:00 https://dev.vigeneron.com/media/sp-global-vigeneron-collaborates-with-biogen-to-develop-gene-therapies-for-eye-diseases/ 2022-05-10T09:27:11+00:00 https://dev.vigeneron.com/media/endpoints-2021-edging-toward-a-pivotal-readout-biogen-picks-a-new-discovery-partner-for-ophthalmic-gene-therapy/ 2022-05-10T09:24:06+00:00 https://dev.vigeneron.com/press/vigeneron-signs-global-collaboration-agreement-for-ophthalmic-gene-therapy-development/ 2021-01-20T12:18:13+00:00 https://dev.vigeneron.com/media/genengnews-vigeneron-and-wuxi-form-strategic-manufacturing-partnership/ 2022-05-09T14:33:33+00:00 https://dev.vigeneron.com/press/vigeneron-and-wuxi-advanced-therapies-enter-strategic-manufacturing-partnership/ 2021-01-18T11:13:06+00:00 https://dev.vigeneron.com/team_member/dr-caroline-man-xu/ 2021-01-17T13:40:25+00:00 https://dev.vigeneron.com/media/pharmaphorum-2019-vigeneron-to-develop-next-gen-eye-gene-therapies-after-funding-round/ 2022-05-10T09:25:30+00:00 https://dev.vigeneron.com/press/vigeneron-announces-closing-of-series-a-financing-to-drive-development-of-next-generation-gene-therapy-pipeline/ 2021-01-18T11:13:22+00:00